Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Stephan Faderl"'
Autor:
Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Barry Storer, Sherry Pierce, Jianqin Shan, Stephan Faderl, Elihu H. Estey
Publikováno v:
Haematologica, Vol 98, Iss 1 (2013)
We recently reported that clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (GCLAC) produced a 46% complete remission rate in relapsed/refractory acute myeloid leukemia. GCLAC differs from FLAG by substitution of clofarabin
Externí odkaz:
https://doaj.org/article/6cea6b8f821348d5a39a4bc87ddfe834
Autor:
Elihu H. Estey, Hagop M. Kantarjian, Stephan Faderl, Jianqin Shan, Barry E. Storer, Andrei R. Shustov, Stephen H. Petersdorf, Sherry Pierce, Derek L. Stirewalt, John M. Pagel, Paul C. Hendrie, Elizabeth Harrington, Frederick R. Appelbaum, Pamela S. Becker
Publikováno v:
British Journal of Haematology. 155:182-189
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patient
Autor:
Tapan M. Kadia, Jessica K. Altman, Olatoyosi Odenike, Martin S. Tallman, Anna Osmukhina, Stephan Faderl, G. Garcia-Manero, K. Wu, S. Padmanabhan, K. Sankhala, Gregory A. Curt, G. Borthukar, Wendy Stock, Dennis Huszar, J. Li, Hagop M. Kantarjian, Mark D. Minden
Publikováno v:
Investigational New Drugs. 30:1107-1115
Eg5 (kinesin spindle protein) is a microtubule motor protein, essential for centrosome separation during mitosis. This Phase I/II, open-label, multicenter, two-part study investigated AZD4877, a potent Eg5 inhibitor, in patients with acute myeloid le
Autor:
Zeev Estrov, G. Garcia-Manero, Sherry Pierce, M. Andreeff, Keith W. Pratz, E. Jabbour, Hagop M. Kantarjian, Jorge E. Cortes, R. Luthra, Deborah A. Thomas, Marina Konopleva, Mark J. Levis, Mark Brandt, Farhad Ravandi, Stephan Faderl, Susan O'Brien, G. Borthakur, C. Arana Yi
Publikováno v:
Leukemia. 28:1543-1545
Sorafenib is a multikinase inhibitor and a potent FLT3 inhibitor that inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases and cell surface kinase receptors such as VEGFR, PDGFR-beta, cKIT, and FLT-3.1 It has been approved b
Autor:
Michael J. Keating, Farhad Ravandi, J. E. Cortes, Charles Koller, Sherry Pierce, Fabio P.S. Santos, G. Borthakur, Stephan Faderl, Hagop M. Kantarjian, Emil J. Freireich, C. E. Bueso-Ramos, G. Garcia-Manero, M. de Lima, Miloslav Beran, Susan O'Brien, X. Huang
Publikováno v:
Leukemia. 23:2275-2280
Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas–M.D.
Publikováno v:
Leukemia. 23:457-466
Recent advances in purine analog-based combination chemotherapy and chemoimmunotherapy have significantly improved response rates and progression-free survival in patients with B-cell chronic lymphocytic leukemia (CLL). However, there are clinical sc
Autor:
Susan Lerner, Susan O'Brien, Stephan Faderl, William G. Wierda, A. Ferrajoli, Constantine S. Tam, Apostolia Maria Tsimberidou, Mary L. Browning, Hagop M. Kantarjian, Issa F. Khouri
Publikováno v:
Leukemia & Lymphoma. 48:1931-1939
The natural history and outcome of salvage treatment for patients with fludarabine-refractory chronic lymphocytic leukemia who are either refractory to alemtuzumab ("double-refractory") or ineligible for alemtuzumab due to bulky lymphadenopathy ("bul
Autor:
Elias Anaissie, Stephan Faderl, Maureen Cooper, Alison L. Hannah, Maurizio Zangari, Nguyen Tan, Maher Albitar, Alison Stopeck, Guillermo Garcia-Manero, Hagop M. Kantarjian, Julie M. Cherrington, Francis J. Giles, Alyssa Morimoto, Jeffrey E. Lancet
Publikováno v:
Clinical Cancer Research. 10:88-95
Purpose: Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with multiple myeloma (MM). VEGF, a soluble circulating angiogenic molecule, acts via receptor tyrosin
Autor:
Anna Rogers, Maher Albitar, Francis J. Giles, B. Nebiyou Bekele, Susan O'Brien, Stephan Faderl, Hagop M. Kantarjian, Jorge E. Cortes, Michael J. Keating, Moshe Talpaz, Taghi Manshouri, Deborah A. Thomas
Publikováno v:
British Journal of Haematology. 119:38-45
Summary. Increased angiogenesis is important in the pathophysiology of haematological malignancies. Cyclooxygenase-2 (Cox-2) converts arachidonic acid to prostaglandins, which induce expression of angiogenic factors, including vascular endothelial gr
Autor:
Cristi Gidel, Taghi Manshouri, Stephan Faderl, Maher Albitar, Hagop M. Kantarjian, M. Keating
Publikováno v:
Leukemia Research. 25:39-43
Cytogenetic abnormalities are among the most important pretreatment predictors of outcome in patients with acute lymphoblastic leukemia (ALL). Deletions of genetic material can result in loss of tumor suppressor genes or other translation products th